Business
Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office
Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Tra...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\nResverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nCALGARY, March 15, 2017\n\n\n\nCALGARY, March 15, 2017 /CNW/ - Resverlogix Corp. (\"Resverlogix\" or the \"Company\") (TSX: RVX) today announced the receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent claims covering the use of apabetalone in combination with Rosuvastatin in the United States. Rosuvastatin was exclusively marketed by AstraZeneca under the trade name Crestor® until its patent expired in 2016. The allowed patent is entitled: \"Compositions and Therapeutic Methods for Accelerated Plaque Regression,\" and covers claims for both a single composition as well as separate compositions of the two drugs.  Resverlogix has similar claims pending in other jurisdictions.\n\n\"We are very pleased with the allowance of one of the key patents, covering the combination of apabetalone with one of the most successful statins on the market.  It further solidifies Resverlogix as a key player in the cardiovascular disease market,\" stated Donald McCaffrey, President & Chief Executive Officer.\n\nMr. McCaffrey further stated, \"Resverlogix devotes significant resources to ensure the protection of ideas and inventions related to the core areas of our business. We believe that our know-how in multiple disease areas will provide a significant competitive advantage. We intend to continue to develop and protect our proprietary tools, methods, and trade secrets.\"  \n\nAbout Resverlogix\n\nResverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biolog...